Quetmolimab: A Deep Dive into KANAb 001 and E-6011 The compound, quetmolimab, represents a new immunotherapy targeting the PD-1 receptor. First study findings from both programs, KANAb 001 and E-6011, reveal https://mediajx.com/story27920290/text